Dr. Surendra S. Barshikar, M.D.
Physical Medicine & Rehabilitation (PM&R) (Physical Medicine & Rehabilitation Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 196
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Physical Medicine & Rehabilitation Physician primary
TX license Q8019 (first issued 2016; active) · NJ license 25MA09092800 -
Brain Injury Medicine (Physical Medicine & Rehabilitation) Physician
TX license Q8019 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- Ut of Texas Southwestern University Hospital - William P. Clements Jr. Dallas, TX
- Parkland Health & Hospital System Dallas, TX
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 196
- Services billed
- 487
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 68 | 38 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 55 | 40 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 48 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 43 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 27 | 18 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 19 | 14 |
| Established patient office or other outpatient visit, 40-54 minutes | 14 | 14 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Baclofen Other prescribers in Dallas, TX | 50 |
| Gabapentin Other prescribers in Dallas, TX | 26 |
| Duloxetine Hcl Other prescribers in Dallas, TX | 21 |
| Amantadine (amantadine hcl) Other prescribers in Dallas, TX | 16 |
| Amitriptyline Hcl Other prescribers in Dallas, TX | 13 |
| Tizanidine Hcl Other prescribers in Dallas, TX | 12 |
| Trazodone Hcl Other prescribers in Dallas, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $108 in total to this clinician.
| AbbVie Inc. | $55.04 |
|---|---|
| Ipsen Biopharmaceuticals, Inc | $52.92 |
| Food and Beverage | $108 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $25,719 in research payments for these studies, mostly to the institutions running them.
- Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
Csl Behring · Terminated · NCT06524739
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.